Researchers from the Netherlands have experienced a new, minimally invasive procedure of rejuvenating the inner walls of the duodenum, combined with daily intake of a drug that reduces glucose levels and minor lifestyle changes. It has turned out that the revolutionary endoscopy therapy can lead to the cessation of insulin intake among a significant number of patients with type 2 diabetes.
Specialists from the University of Amsterdam have developed a set of measures to help patients with type 2 diabetes to stop taking insulin injections. The minimally invasive method of duodenal mucosa recovery (Duodenal Mucosal Resurfacing, DMR) is performed in outpatient conditions through a special controlled catheter that performs the amputation of the treated area.
Although the underlying process is not completely clear, the mucous membrane cells undergo changes as a result of eating harmful foods high in fat and sugar. This leads to changes in the production of key hormones that affect insulin resistance. Mucosal regeneration rejuvenates cells and allows the body to more effectively resist diabetes, writes EurekAlert.
The study involved 16 patients who underwent DMR procedure, as well as received daily doses of lowering the level of sugar (GLP-1 RAs), and refused the most harmful products. Six months later, 75% of them were able to refuse insulin injections.
The HbA1c indicator, a parameter of long-term glucose control, fell to 7.5% or less in these experimental treatment participants. After 12 months, it fell to 6.7%.
Patients who underwent treatment noted a significant decrease in the body mass index: on average, from 29.8 kg/m2 at the beginning of the study to 25.5 kg/m2 a year later. The proportion of fat in the liver also decreased from 8.1% to 4.6% after six months.
A quarter of patients who did not respond to this level of treatment were able to reduce their insulin dose by more than half, from 35 units per day to 17 units per day after 12 months.
Scientists believe that this therapy can be a breakthrough in the treatment of metabolic syndrome. And they hope that soon a major study will be conducted in Europe, which will confirm the effectiveness of DMR.